Monoclonal Antibodies: How Targeted Therapy Directs Immunity

Monoclonal antibodies are lab-made proteins cloned from one white blood cell line to bind a single target in the body. Natural polyclonal defenses mix different proteins against many surface tags, but each monoclonal batch contains exact copies with monovalent affinity [3]. The adaptive immune system naturally uses antibodies to tag foreign invaders, but regular plasma cells cannot always mount a sustained attack against hiding tumors or destructive autoimmune reactions that damage healthy organs [4]. Each clone traces back to one parent cell [3]. By growing one chosen cell clone, researchers direct immune strikes toward diseased targets while sparing healthy cells [4]. Today, these lab tools shape modern care in oncology, rheumatology, and infectious disease [2].

What Are Monoclonal Antibodies?

An antibody is a defensive protein made by B cells to spot foreign antigens like viruses, bacteria, and toxins [2]. In a normal immune response, many plasma cell lines produce mixed polyclonal pools that bind across different parts of an antigen. A monoclonal clone comes from one parent cell, so every copy hits the exact same target site. Do synthetic clones bind tighter? Cloned cells yield identical proteins that bind one site without variation [3].

The physical shape of an immunoglobulin G (IgG) protein explains its targeting precision. Weighing about 150 kDa, an IgG antibody has two heavy chains of roughly 50 kDa and two light chains near 25 kDa, joined by flexible chemical bonds. Light chains appear as either kappa (κ) or lambda (λ) forms. Treatment with the plant enzyme papain splits the structure into two antigen-binding Fab arms and one crystallizable Fc stem. The Fab arms hold hypervariable loops that bind targets, while the constant Fc stem signals immune cells like macrophages and natural killer cells to destroy the tagged threat [4]. In human biology, antibodies span five classes including IgG, IgA, IgM, IgD, and IgE, but IgG serves as the chief template for clinical drugs [3, 6].

How Hybridoma Technology Began

The idea of targeted therapy began in the early 1900s when German immunologist Paul Ehrlich imagined a “magic bullet” that could wipe out microbes without harming bodily organs. Ehrlich shared the 1908 Nobel Prize with Élie Metchnikoff for laying the groundwork of immunology, but isolating single antibodies remained out of reach [3]. In 1951, Henry Kunkel at the Rockefeller Institute in New York found that malignant plasma cells from patients with multiple myeloma made huge amounts of a single identical antibody [1].

Michael Potter at the National Cancer Institute in Bethesda discovered in 1962 that injecting mineral oil into the abdomen of BALB/c mice triggered myeloma cell growth. This gave researchers a stable supply of malignant cells. In 1970, Kengo Horibata and A.W. Harris, working under Melvin Cohn at the Salk Institute in San Diego, adapted Potter’s mouse line MOPC21 to grow in continuous liquid culture. Their work freed researchers from growing cells inside live animals [1].

At the Laboratory of Molecular Biology in Cambridge, César Milstein and Georges Köhler solved the cell lifespan puzzle in 1975 by fusing antibody-producing mouse spleen B cells with immortal myeloma cells. Working with Alan Munro, George Brownlee, and Dick Cotton, the team used polyethylene glycol to merge cell walls before culturing them in selective HAT medium containing hypoxanthine, aminopterin, and thymidine [1, 3]. Because the myeloma parent lacked the salvage enzyme HGPRT, only fused hybrid cells survived and grew indefinitely. Köhler and Milstein shared the 1984 Nobel Prize with Niels Kaj Jerne for this work, which let scientists build custom cell factories for any chosen target [3].

Evolution of Engineered Proteins

Early drug candidates grown from rodent hybridomas hit severe roadblocks because the human body saw mouse proteins as foreign threats. These early mouse drugs, marked by the name ending -omab, triggered host anti-mouse antibodies that cleared the medicine quickly or caused fever and hives. To fix this problem, molecular biologists used gene-splicing tools to swap rodent protein parts with human sequences [4].

Chimeric antibodies, using the stem -ximab, fused mouse variable domains onto human constant domains taken from IgG1 heavy chains and kappa light chains. This switch made the molecules 65% to 75% human, lowering immune rejection while keeping the drug in the bloodstream far longer. In 1988, Gregory Winter at Cambridge built humanization methods that improved antibody design by moving only the rodent complementarity-determining loops (CDRs) onto human protein frameworks, yielding drugs that were 95% human in makeup [3, 4]. These humanized agents carry the stem -zumab. Framework changes can weaken target grip. Work with transgenic mice and phage display yielded fully human antibodies ending in -umab [4]. Modern bioreactors now brew these drugs cleanly without animal fluid harvesting [3].

The Updated WHO Naming Scheme

For decades, health regulators gave generic drug names ending in the single stem -mab to every antibody product. The old system used syllable codes for targets, such as ci for heart vessels, lim for white blood cells, and tu for tumors. As drug makers built complex multi-target designs and smaller fragments, the old list became overloaded [5]. In late 2021 and May 2022, the World Health Organization (WHO) International Nonproprietary Names (INN) team, working with the USAN Council, launched a four-group naming rule for all new antibody submissions [6, 7].

Under the revised WHO rules, unmodified antibodies that match natural human proteins receive the stem -tug. This group covers plain IgG, IgA, IgM, IgD, and IgE drugs with natural constant domains. Monospecific antibodies engineered with point mutations in their constant regions take the stem -bart to mark artificial changes that alter cell binding or sugar chains [6, 7]. Multi-target constructs like bispecific BiTEs or TriKEs take the stem -mig, no matter their shape [5, 6]. Single-target fragments without an Fc stem, such as Fab pieces or single-chain variable fragments (scFv), now carry the stem -ment [6, 7].

Read these too!

ESMO 2026 Congress Presents Phase 3 Oncology Data

25 October 2026

B Cells Vs T Cells: How Adaptive Immunity Fights Pathogens

24 October 2026

3 views

How Monoclonal Antibodies Target Disease

Monoclonal antibodies fight disease through several clear cell pathways. In oncology, these proteins block signal switches that malignant cells use to hide from body defenses [4]. James P. Allison and Tasuku Honjo won the 2018 Nobel Prize for showing how checkpoint inhibitors turn off these immune brakes [3]. When an antibody binds to checkpoint receptors, cytotoxic T cells can find and kill tumor cells directly [2, 4]. Other antibodies rely on antibody-dependent cellular cytotoxicity (ADCC), calling in natural killer cells to wipe out tumor targets marked by the antibody Fc tail [4, 9].

New clinical trial data show how precise antibody binding prolongs patient lives. At the IASLC 2026 World Conference on Lung Cancer, researchers shared stage 1 results from the phase III PRESERVE-003 trial testing gotistobart in metastatic squamous non-small cell lung cancer [8].

Gotistobart is an investigational anti-CTLA-4 antibody built to clear regulatory T cells inside tumors. In the trial, patients taking gotistobart reached a median overall survival of 18.5 months, compared with 10.0 months for patients on docetaxel chemotherapy. Presenting author Dr. Rama Balaraman of the Ocala Oncology Center noted that the drug cut the risk of death by 43%, with a hazard ratio of 0.572. “The updated survival findings reinforce the potential of gotistobart to provide a meaningful new treatment option for patients with metastatic squamous NSCLC whose disease has progressed following PD-1/-L1 therapy,” Balaraman said [8].

Clinical Uses of Monoclonal Antibodies

The US approval of rituximab (Rituxan) for follicular lymphoma in late 1997 opened the modern era of antibody treatments [3, 12]. In cancer care, drugs like trastuzumab (Herceptin), cetuximab (Erbitux), and pembrolizumab (Keytruda) bind tumor markers to halt malignant spread [2]. In a market study in mAbs, researchers D.M. Ecker, S.D. Jones, and H.L. Levine noted that 47 monoclonal antibody products were approved in the United States and Europe by late 2014, heading toward roughly 70 products by 2020 [16]. Other projects, like bavituximab (3G4, Tarvacin) from Avid Bioservices and MD Anderson Cancer Center, tested targeting phosphatidylserine across lung cancer and viral infections [9].

Beyond cancer, these targeted drugs calm severe autoimmune attacks where older pills fail. Biologics like adalimumab (Humira) and infliximab (Remicade) block tumor necrosis factor to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. In brain conditions, natalizumab (Tysabri) curbs nervous system swelling in multiple sclerosis, while belimumab (Benlysta) manages systemic lupus erythematosus [2].

These proteins also protect organ transplants and balance metabolic hormones. Basiliximab (Simulect) and daclizumab block interleukin-2 receptors on T cells to protect donor kidneys from graft rejection [2]. In diabetes care, K.C. Herold and colleagues reported in the New England Journal of Medicine that a two-week course of an anti-CD3 antibody kept insulin output steady in 9 of 12 new-onset type 1 diabetes patients after one year, against only 2 of 12 control patients [11]. In heart health, E.A. Stein and coworkers showed that antibodies against PCSK9 sharply lower LDL cholesterol [14]. In infectious disease, M.R. Gaudinski and coworkers showed that the long-acting antibody CIS43LS guarded healthy adults against malaria, with a circulating half-life of 56 days [15].

Manufacturing and Purification

Making therapeutic proteins in large supply is an exacting craft that requires suitable living host cells. Because full-length IgG antibodies need complex human-like sugar branching to remain stable and active, drug firms grow them inside mammalian host cells within large stainless steel tanks [10, 13]. Simple microbes like Escherichia coli or Pichia pastoris lack sugar-adding enzymes, but work well for small unglycosylated antibody pieces [10]. During growth and bottling, process teams watch closely for protein clumps. Clumped proteins can weaken drug potency and trigger unwanted immune flares in treated patients [13].

Purification pulls the clean drug from crude broth through several filtration and resin steps. Initial harvesting uses spinning and filtration through a 0.45 μm filter to clear whole cells, oily fats, and debris before fluid reaches fine chromatography beads. Because host proteins carry different electrical charges, ion exchange columns bind unwanted nucleic acids and bacterial toxins. Human albumin has an electrical balance point (pI) of 4.8, while monoclonal antibodies average around 6.1, allowing clean separation by tuning fluid pH. Protein A or G resin columns then grab the antibody Fc tail, reaching over 80% purity in one pass. Mild salty wash buffers help release fragile proteins without harsh acid damage [3].

Side Effects and Clinical Safety

Monoclonal antibodies come as freeze-dried powders for mixing or liquid vials for slow intravenous drips and shallow skin shots. Biologics avoid the broad cell poisoning seen with chemotherapy, but intravenous infusions can still trigger quick bodily reactions. Patients may feel mild chills, fever, weakness, nausea, headache, itching, or skin hives, most often during their first or second hospital clinic visit [2, 12]. Doctors give allergy pills, acetaminophen, or steroid shots before treatment to prevent these infusion reactions. Severe throat swelling or sudden blood pressure drops happen rarely, requiring fast medical help and immediate drip shutdown [2, 12]. C.H. Chung reported in The Oncologist that premedication may no longer be needed after the second infusion for certain agents like cetuximab [12].

Patients on antibody therapy need regular health checks for long-term safety and drug clashes. Pairing immune-calming antibodies with daily steroid pills raises the risk of deep lung and blood infections. Drug tests show that methotrexate drops the absorption of adalimumab by 29% to 49%, yet standard clinic dosing stays the same without extra adjustments. Because these drugs quiet immune memory, live weakened vaccines should not be given during treatment. For pregnant or nursing mothers, clinical safety data remain scarce; drugs like pembrolizumab may endanger fetal growth, and large proteins can pass into mother’s milk. Weighing these factors helps doctors guide patient care safely [2].

1. ^WEBSITE What Is Biotechnology. (2008). The Story of César Milstein and Monoclonal Antibodies. [Article Link]
2. ^WEBSITE Ogbru, O. (2022). Monoclonal Antibodies: Uses, Types, Side Effects & COVID-19. MedicineNet. [Article Link]
3. ^WEBSITE Wikipedia contributors. (n.d.). Monoclonal antibody. Wikipedia, The Free Encyclopedia. [Article Link]
4. ^WEBSITE Wikipedia contributors. (n.d.). Monoclonal antibody therapy. Wikipedia, The Free Encyclopedia. [Article Link]
5. ^WEBSITE Wikipedia contributors. (n.d.). Nomenclature of monoclonal antibodies. Wikipedia, The Free Encyclopedia. [Article Link]
6. ^REPORT World Health Organization. (2021). New INN monoclonal antibody (mAb) nomenclature scheme (INN Working Document 21-531). [Article Link]
7. ^REPORT World Health Organization. (2022). New INN monoclonal antibody (mAb) nomenclature scheme (INN Working Document 22-542). [Article Link]
8. ^{ONLINE NEWS} The ASCO Post Staff. (2026). Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC. The ASCO Post. [Article Link]
9. ^WEBSITE Springer Nature. (2026). Bavituximab – Avid Bioservices. AdisInsight. [Article Link]
10. ^{ACADEMIC JOURNAL} A, O. S., Capone, S., Krainer, F., Glieder, A., & Herwig, C. (2013). Microbials for the production of monoclonal antibodies and antibody fragments. Trends in Biotechnology, 32(1), 54-60. [Article Link]
11. ^{ACADEMIC JOURNAL} Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., & Bluestone, J. A. (2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. New England Journal of Medicine, 346(22), 1692-1698. [Article Link]
12. ^{ACADEMIC JOURNAL} Chung, C. H. (2008). Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy. The Oncologist, 13(6), 725-732. [Article Link]
13. ^{ACADEMIC JOURNAL} Vázquez‐Rey, M., & Lang, D. (2011). Aggregates in monoclonal antibody manufacturing processes. Biotechnology and Bioengineering, 108(7), 1494-1508. [Article Link]
14. ^{ACADEMIC JOURNAL} Stein, E. A., Mellis, S. J., Yancopoulos, G. D., Stahl, N., Logan, D. K., Smith, W. B., Lisbon, E. A., Gutierrez, M., Webb, C. B., Wu, R., Du, Y. E., Kranz, T., Gasparino, E., & Swergold, G. D. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. New England Journal of Medicine, 366(12), 1108-1118. [Article Link]
15. ^{ACADEMIC JOURNAL} Gaudinski, M. R., Berkowitz, N. M., Idris, A. H., Coates, E. E., Holman, L. A., Mendoza, F., Gordon, I. J., Plummer, S. H., Trofymenko, O., Hu, Z., Chagas, A. C., O’Connell, S., Basappa, M., Douek, N., Narpala, S. R., Barry, C. R., Widge, A. T., Hicks, R., Awan, S. F., & Evans, B. P. (2021). A Monoclonal Antibody for Malaria Prevention. New England Journal of Medicine, 385(9), 803-814. [Article Link]
16. ^{ACADEMIC JOURNAL} Ecker, D. M., Jones, S. D., & Levine, H. L. (2014). The therapeutic monoclonal antibody market. mAbs, 7(1), 9-14. [Article Link]